Yafit Tehila - 29 May 2026 Form 4 Insider Report for QTREX Quantum Ltd. (QTEX)

Reporting relationship: Chief Financial Officer
Issuer ticker: QTEX
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 16:01:35 UTC
Prior SEC filing: 29 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Yafit Tehila

Key filing fact

Yafit Tehila filed Form 4 for QTREX Quantum Ltd. (QTEX) on 02 Jun 2026.

Key facts

This page summarizes Yafit Tehila's Form 4 filing for QTREX Quantum Ltd. (QTEX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2026, 16:01.

Change

Previous filing in this sequence was filed on 29 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001971352 Primary reporting owner

Tehila Yafit

Relationship: Chief Financial Officer
Address: 2 HA-TIDHAR ST., RA'ANANA, ISRAEL
Signature: /s/ Yafit Tehila
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QTEX transaction

Ordinary Shares

Sale

Transaction value
Shares: -1,900
Change %: -0.21%
Price: $3.51^*
Shares after: 898,100
Date: 29 May 2026
Ownership: Direct
Footnotes: F1

QTEX transaction

Ordinary Shares

Sale

Transaction value
Shares: -28,100
Change %: -3.1%
Price: $3.50^*
Shares after: 870,000
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold. The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.